Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xlucane versus Lucentis in neovascular age-related macular degeneration
MOH_2019-06-20_007211Phase 3Recruiting
- Sponsor
- Xbrane
- Start
- Jun 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Lucentis with Xlucane investigational product (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2019; status: recruiting.
02
Drugs
xlucaneranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2019-06-20_007211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-20_007211.